"Bringing the best treatments to the most people where they live"

During the past decade, Prolato Clinical Research Center conducted 17 clinical trials. In the 10-year time frame, 17 clinical trials started and 1 clinical trials were completed, i.e. on average, 5.9% percent of trials that started reached the finish line to date. In the past 5 years, 16 clinical trials started and 1 clinical trials were completed. i.e. 6.3% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Prolato Clinical Research Center" #1 sponsor was "Chinook Therapeutics U.S., Inc." with 2 trials, followed by "Goldfinch Bio, Inc." with 2 trials sponsored, "Hoffmann-La Roche" with 2 trials sponsored, "Pfizer" with 2 trials sponsored and "Vertex Pharmaceuticals Incorporated" with 2 trials sponsored. Other sponsors include 2 different institutions and companies that sponsored additional 12 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Prolato Clinical Research Center" #1 collaborator was "ADIR, a Servier Group company" with 1 trials as a collaborator, "Biocon Limited" with 1 trials as a collaborator and "Centessa Pharmaceuticals plc" with 1 trials as a collaborator. Other collaborators include -3 different institutions and companies that were collaborators in the rest 3 trials.

According to Clinical.Site data, the most researched conditions in "Prolato Clinical Research Center" are "IgA Nephropathy" (3 trials), "Glomerulonephritis" (2 trials), "Glomerulosclerosis, Focal Segmental" (2 trials), "Immunoglobulin A Nephropathy" (2 trials) and "Kidney Diseases" (2 trials). Many other conditions were trialed in "Prolato Clinical Research Center" in a lesser frequency.

Most popular intervention types in "Prolato Clinical Research Center" are "Drug" (16 trials) and "Biological" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (7 trials), "Atrasentan" (2 trials), "GFB-887" (2 trials), "Methylprednisolone" (2 trials) and "Obinutuzumab" (2 trials). Other intervention names were less common.

The vast majority of trials in "Prolato Clinical Research Center" are 17 trials for "All" genders.

Currently, there are NaN active trials in "Prolato Clinical Research Center". undefined are not yet recruiting, 9 are recruiting, 2 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 2 completed trials in Prolato Clinical Research Center, undefined suspended trials, and 4 terminated clinical trials to date.

Out of the total trials that were conducted in Prolato Clinical Research Center, 3 "Phase 1" clinical trials were conducted, 11 "Phase 2" clinical trials and 6 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".